In a phase 2 trial in 104 patients with stage II-III HER2-positive breast cancer, neoadjuvant TQB2102 gave total pathologic complete response in 57.7% to 76.9% across four dose/cycle cohorts; grade ≥3 treatment-related adverse events were 23.1% to 30.8%.
RCTn = 104
Li et al. Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial